Diagnostics Manufacturing Facility Launches in India to Service Growing Indian Healthcare Market

New York, New York, UNITED STATES

New York City, April 25, 2019 (GLOBE NEWSWIRE) --

The long-awaited molecular diagnostics manufacturing facility for the Indian joint venture between Co-Diagnostics Inc. and Synbiotics Pvt Ltd has finally launched, according to news released last week.

BDA International client company Co-Diagnostics first announced the formation of the CoSara Diagnostics Pvt Ltd joint venture with Synbiotics in 2017. Since that time, shareholders have been eager for any news or updates concerning the completion of the facility that was described as one of the first of its kind in India, and is expected to provide molecular diagnostics across the country of India (nearly 18% of the world’s population, and expected to grow into the world’s largest single healthcare market in the next several years).

Co-Diagnostics, Inc. (CODX), a Nasdaq-listed Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).

Synbiotics is an Indian pharmaceutical manufacturing company, whose management and operations teams have vast experience setting up state-of-the-art manufacturing MedTech manufacturing facilities, including compliance with all national and international regulatory requirements (WHO-GMP, US FDA, EU-GMP, etc). All commercial operations are undertaken by Asence Inc, a U.S. company that specializes in supplying pharmaceutical products to international markets. Both Synbiotics and Asence are subsidiaries of Ambalal Sarabhai Enterprises Ltd., or ASE, a continuation of one of the oldest and most respected manufacturing institutions in India in operation today.  The Sarabhai family has run the company since its inception as textile mills in the 19th century, building an empire that in modern times has led to ASE being synonymous with trusted, quality pharmaceuticals.

The press announcement included that the CoSara facility is not only complete, but was also planned to allow for further expansion in the future. Stakeholders in CODX should be able to breathe a sigh of relief that Co-Diagnostics now has the operational capacity, logistical/compliance support, and valuable connections that will facilitate revenue growth in their infectious disease initiative and access to an important global healthcare market.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles may also in some circumstances hold some of shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.


Co-Diagnostics is a client of BDA International. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:                                                                               
BDA International